<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649909</url>
  </required_header>
  <id_info>
    <org_study_id>0020-08-HMO-CTIL</org_study_id>
    <nct_id>NCT00649909</nct_id>
  </id_info>
  <brief_title>Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients</brief_title>
  <official_title>Effect of Glucose Control on the Response to Aspirin in Type 2 Diabetic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of low dose aspirin appears to be substantially lower in diabetic patients,
      compared to patients without diabetes.

      We will perform an observational study where we follow up patients with uncontrolled type 2
      Diabetes Mellitus and low response to aspirin (Aspirin Resistance), during a period of 6
      months in the diabetic clinic. Our hypothesis is that glucose control will improve the
      response to aspirin in those patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The outcome measure is the laboratory Aspirin Resistance.</measure>
    <time_frame>3 and 6 months.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the incidence of laboratory aspirin resistance in type 2 DM in stable out-patients in the diabetic clinic, and possibly related factors.</measure>
    <time_frame>On screening visit.</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Diabetes Mellitus, Type II</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Type 2 diabetic patients with reduced laboratory response to aspirin.(Aspirin Resistance)and with HbA1c &gt;8%.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 diabetic patients that take aspirin, from the diabetology clinic.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Type 2 DM.

          2. Patients that take aspirin.

          3. Antecubital forearm veins allowing technically good sampling for platelet studies.

          4. Reduced Laboratory response to aspirin.

          5. HbA1c &gt; 8 %

          6. The physician decides that there is an indication for glucose control.

        Exclusion Criteria:

          1. Acute ischemic stroke, acute coronary syndrome, (myocardial infarction or unstable
             angina pectoris), or revascularization by PCI or by-pass surgery within the last 6
             months.

          2. Acute kidney disease or chronic kidney disease with creatinine clearance &lt;30.

          3. Acute liver disease or chronic liver disease with severe liver impairment.

          4. Need for treatment with anticoagulants, clopidogrel, NSAID's, or thiazolidinediones.

          5. Thrombocytopenia (platelet count &lt;150 x 109/L)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Varon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hematology Department, Hadassah Medical Organization, Jerusalem, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>August 9, 2017</last_update_submitted>
  <last_update_submitted_qc>August 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hadassah Medical Organization</investigator_affiliation>
    <investigator_full_name>David Varon</investigator_full_name>
    <investigator_title>Director of coagulation unit</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Type II</keyword>
  <keyword>Aspirin</keyword>
  <keyword>Resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

